Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific Officer

Core Insights - Nuvalent, Inc. has promoted Henry Pelish, Ph.D., to Chief Scientific Officer, reflecting his significant contributions to the company and its mission in cancer therapy development [1][7] - Dr. Pelish has been with Nuvalent since 2018, overseeing the development of key investigational drugs and has over 15 years of experience in cancer biology and chemistry [2][7] - The company focuses on creating targeted therapies for cancer, specifically for clinically proven kinase targets, and aims to address limitations of existing treatments [7] Company Overview - Nuvalent, Inc. is a clinical-stage biopharmaceutical company that develops precisely targeted therapies for cancer [1][7] - The company leverages expertise in chemistry and structure-based drug design to create innovative small molecules that can overcome resistance and minimize adverse events [7] - Nuvalent is advancing a robust pipeline, including investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, along with multiple discovery-stage research programs [7]